National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 2 of 2 Research Studies DisplayedSharma AE, Khoong EC, Rivadeneira N
Warfarin monitoring in safety-net health systems: analysis by race/ethnicity and language preference.
This study’s objective was to determine if there were any race/ethnicity or language disparities in warfarin monitoring in safety-net systems using differences in international normalized ratio (INR) monitoring. This cross-section analysis used process and safety data shared from the Safety Promotion Action Research and Knowledge Network (SPARK-Net) initiative, a consortium of five California safety-net hospital systems. A total of 8129 patients were included: 3615 (44%) were female; 1470 (18%), Black/African American; 3354 (41%), Hispanic/Latinx; 1210 (15%), Asian; 1643 (20%), White; and 452 (6%), other. A total of 45% were non-English preferring. The authors did not observe statistically significant disparities in the rate of appropriate INR monitoring by race/ethnicity or language. The primary source of variation was by healthcare network.
AHRQ-funded; HS024426.
Citation: Sharma AE, Khoong EC, Rivadeneira N .
Warfarin monitoring in safety-net health systems: analysis by race/ethnicity and language preference.
J Gen Intern Med 2022 Aug;37(11):2703-10. doi: 10.1007/s11606-021-07283-6..
Keywords: Blood Thinners, Medication, Racial and Ethnic Minorities
Duconge J, Cadilla CL, Seip RL
Why admixture matters in genetically-guided therapy: missed targets in the COAG and EU-PACT trials.
It is now well recognized that these commonly used pharmacogenetic algorithms perform poorly when applied to people with substantial African heritage. The authors of this letter conclude that the best approach for global pharmacogenetics is to guide warfarin dosing by using a pharmacogenetic-based algorithm that also accounts for the effect of admixture or ancestry proportions.
AHRQ-funded; HS022304.
Citation: Duconge J, Cadilla CL, Seip RL .
Why admixture matters in genetically-guided therapy: missed targets in the COAG and EU-PACT trials.
P R Health Sci J 2015 Sep;34(3):175-7..
Keywords: Racial and Ethnic Minorities, Genetics, Blood Thinners, Medication